GRAIL, Inc. is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- Nano Dimension and Infinite Epigenetics announced a proposed stock-for-stock merger valuing Infinite at $890 million, with Nano shares valued at a 20% premium to estimated net cash at closing. - The combined company will leverage Infinite's proprietary biological AI platform, a CLIA-certified methylation laboratory, and a database of over 120,000 biological samples across a network of more than 7,500 healthcare providers. - Infinite's platform targets earlier and more precise chronic disease detection through DNA methylation-based diagnostics, combining clinical testing, consumer longevity, pharma data, and enterprise health applications. - A definitive agreement is expected before July 31, 2026, with the combined company projected to hold over $400 million in cash at closing.
- Multi-cancer early detection (MCED) tests like Galleri and colorectal cancer blood tests like Shield are reshaping cancer screening, but their impact on mortality remains unproven. - The NHS-Galleri trial of 142,000 adults showed Galleri increased cancer detection fourfold and shifted diagnoses toward earlier stages, yet survival benefit data are still lacking. - Guardant Health's Shield, the first FDA-approved blood-based colorectal cancer screening test, demonstrated 83% sensitivity and 90% specificity in a 20,000-participant trial. - A real-world case highlights how blood-based screening caught Stage 3 colorectal cancer in an asymptomatic patient three years before her next scheduled colonoscopy.
- Mercy is participating in the three-year REACH study evaluating GRAIL's Galleri multi-cancer early detection blood test among up to 50,000 Medicare beneficiaries. - The study will compare Medicare patients receiving annual Galleri testing alongside standard care to those receiving care without the test, focusing on recruiting traditionally underrepresented populations. - Medicare beneficiaries face critical unmet needs for early cancer detection, with almost 70% of cancer deaths in the U.S. occurring in people aged 65 and older. - More than half of all cancer diagnoses in the U.S. occur among Medicare beneficiaries who are at highest risk due to age being the most significant cancer risk factor.
- The FDA approved Cleveland Diagnostics' IsoPSA blood test on December 1, 2025, as an aid in prostate biopsy decision-making for men 50 years and older with elevated PSA levels. - The test analyzes prostate cancer-specific structural variants of the PSA protein to distinguish benign PSA elevations from those caused by high-grade cancer. - FDA approval was based on a large-scale prospective study conducted at 14 U.S. sites, addressing the critical need to reduce unnecessary biopsies in the over 1 million men who undergo the procedure annually. - Up to 75% of prostate biopsies are negative for high-grade disease, subjecting millions to invasive procedures with physical risks and emotional stress.
- Strategic alliances in the biomarker industry have accelerated from 2019 to 2025, driven by growing demand for precision medicine, companion diagnostics, and targeted therapies. - Partnerships are dominating the biomarker market, with companies leveraging collaborations to accelerate development and expand market reach through licensing, acquisitions, and strategic alliances. - Rising incidence of chronic diseases like cancer and diabetes, combined with advances in omics and imaging technologies, is fueling increased investment in biomarker-related deals. - Biomarkers are transforming oncology care by enabling companion diagnostics that allow targeted therapies to be administered only to patients likely to benefit, improving efficacy while reducing costs.
- Samsung C&T and Samsung Electronics announced a $110 million strategic investment in GRAIL, a US biotechnology company developing AI-powered early cancer detection technology. - GRAIL's Galleri test can detect approximately 50 types of cancer through a single blood test and has accumulated 400,000 testing records since its 2021 launch. - Samsung C&T secured exclusive distribution rights for Korea and plans expansion to Singapore and Japan, while Samsung Electronics will integrate GRAIL's technology with its Samsung Health platform. - The investment positions Samsung to capitalize on the growing early cancer detection market as GRAIL prepares for FDA approval submission next year.
- The Galleri blood test demonstrated 61.6% accuracy in confirming cancer diagnoses when a positive signal was detected, according to results from the Pathfinder 2 study presented at the European Society for Medical Oncology Congress. - The test detected seven times more cancers than existing screening programs combined and correctly identified the organ or tissue of origin in 92% of cases, with over half of detected cancers being early-stage. - More than 75% of cancers detected by Galleri lack current screening options, potentially addressing a significant gap in cancer detection for diseases like pancreatic, liver, and ovarian cancers. - The NHS is conducting its own 140,000-person trial with results expected mid-2025, which could lead to the UK becoming the first country to implement multi-cancer screening nationally.
- Real-world data from over 100,000 patients confirms Galleri's ability to detect multiple cancer types simultaneously, with high accuracy in predicting cancer signal origin to guide diagnostic evaluations. - GRAIL's modeling analysis demonstrates reduced cancer risk for one year following a negative Galleri test result, supporting the recommendation for annual screening with the multi-cancer early detection test. - New research on GRAIL's ctDNA-based targeted methylation platform shows potential for detecting abnormal promoter methylation and identifying cancer subtypes from a single blood draw, potentially eliminating the need for invasive biopsies.
- GRAIL's ctDNA assay is being used in AstraZeneca's TROPION-Lung12 Phase 3 trial to assess eligibility for adjuvant treatment in Stage I NSCLC patients. - The assay utilizes GRAIL's targeted methylation platform for ctDNA detection, offering a tissue-free approach for integration into clinical trial workflows. - The goal is to identify patients at higher risk of recurrence after surgery who would likely benefit most from adjuvant therapy. - This collaboration between GRAIL and AstraZeneca aims to personalize treatment decisions in early-stage lung cancer using ctDNA insights.
• Grail's Galleri test, designed for early detection of over 50 cancer types from a single blood sample, is seeking FDA approval to broaden its accessibility. • The company is actively working towards FDA premarket approval for Galleri, utilizing data from NHS-Galleri and PATHFINDER 2 studies, aiming for submission by 1H2026. • Cost-cutting measures, including a 30% workforce reduction, aim to extend the company's cash runway and support the pursuit of Medicare coverage post-FDA approval. • Galleri has already seen commercial success as a Laboratory Developed Test, with over 215,000 tests prescribed by 11,000 healthcare providers, highlighting its potential impact.
